Ashok Patidar

Ashok Patidar

Auto-generated profile, based on publicly available information

Ashok Patidar

National Centre for Cell Science Pune India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Cytokine
Verified
Journal Article
Closed access
APAshok Patidar
Ashok Patidar
SSSathishkumar Selvaraj
Sathishkumar Selvaraj
ASAditya Sarode
Aditya Sarode
PCPrashant Chauhan
Prashant Chauhan
DCDebprasad Chattopadhyay
Debprasad Chattopadhyay
BSBhaskar Saha
Bhaskar Saha

4 August 2020 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
APAshok Patidar
Ashok Patidar
TMTrishna Mahanty
Trishna Mahanty
CRChandan Raybarman
Chandan Raybarman
Aditya Yashwant SarodeAditya Yashwant Sarode
Aditya Yashwant Sarode
SBSurajit Basak
Surajit Basak
SBSurajit Bhattacharjee
Surajit Bhattacharjee

1 December 2018 in Cytokine
Verified
Journal Article
Closed access
TPTejaswini Patil
Tejaswini Patil
VMVasundhara More
Vasundhara More
DRDeepti Rane
Deepti Rane
AMArkajyoti Mukherjee
Arkajyoti Mukherjee
RSRahul Suresh
Rahul Suresh
ASArup Sarkar
Arup Sarkar

6 March 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SSSathishkumar Selvaraj
Sathishkumar Selvaraj
MRMahesh Raundhal
Mahesh Raundhal
APAshok Patidar
Ashok Patidar
BSBhaskar Saha
Bhaskar Saha
As its central immunomodulatory effects, CD40 induces interleukin (IL)-12-dependent antitumor immune responses; as its local protumor effects, CD40 induces the expression of vascular endothelial growth factor (VEGF) that promotes tumor angiogenesis and growth. Therefore, using a previously established tumor model in mouse, we examined if the antitumor functions of CD40 are self-limited by VEGF induction. We observed that as the tumor mass grew during day 6 to day 18, VEGF expression in the tumor peaked with concomitant decrease in expressions of CD40 and IL-12 but not of IL-10. Among the angiogenic factors, VEGF-B, VEGFR-1, VEGFR-2, angiopoietin-1 and Tie2 expressions decreased, whereas the expressions of angiopoietin-2 and angiopoietin-3 increased with tumor growth. As significant changes in the expressions of these factors were observed on day 6, we treated the tumor-bearing mice with the agonistic anti-CD40 antibody or neutralizing anti-VEGF antibody—alone or in combination—from the fifth day after the injection of tumor cells. The anti-VEGF antibody significantly enhanced the antitumor effects of the anti-CD40 antibody, as observed through increased survival of the mice, accompanied by reduced angiogenesis and angiopoietin-2 expression but higher T-cell proliferation in response to tumor antigens, increased interferon-γ production and tumor cell cytotoxicity and higher levels of tumor antigen-specific serum IgM, IgG1 and IgG2a, indicating B-cell activation. Thus, our data show for the first time that the combined treatment with an agonistic anti-CD40 antibody and a neutralizing anti-VEGF antibody, which increases antitumor immune response or reduces local angiogenesis, respectively, is a novel antitumor strategy.

1 April 2018 in Cytokine
Verified
Journal Article
Closed access
DSDivanshu Shukla
Divanshu Shukla
HCHimanshu Singh Chandel
Himanshu Singh Chandel
SSSunit Srivastava
Sunit Srivastava
PCPrashant Chauhan
Prashant Chauhan
SPSurya Prakash Pandey
Surya Prakash Pandey
BSBhaskar Saha
Bhaskar Saha

22 May 2021 in Immunology
Verified
Journal Article
Closed access
PDF file
AMArkajyoti Mukherjee
Arkajyoti Mukherjee
SRSayoni Roy
Sayoni Roy
APAshok Patidar
Ashok Patidar
NBNeelam Bodhale
Neelam Bodhale
JDJagneswar Dandapat
Jagneswar Dandapat
ASArup Sarkar
Arup Sarkar